Featured Story | By Annalee Armstrong The pressure is on for Moderna to step up and save the day with a monkeypox vaccine, just as it did for COVID-19. But executives from the famed biotech insist the idea is still in the conceptual phase. read more |
| |
|---|
|
Top Stories By Nick Paul Taylor Roche’s business development team has made a busy start to August. On Wednesday, the Swiss pharma company disclosed deals with Poseida Therapeutics and Kiniksa Pharmaceuticals that are together worth $190 million upfront. read more By Annalee Armstrong It’s going to be a long wait, but RegenXBio is already waving a flag to show that the Hunter syndrome gene therapy RGX-121 is headed for an accelerated approval request at the FDA. read more By Max Bayer Another quarter, another cull for Moderna. The company snuck into its second-quarter earnings report that development of an mRNA treatment for IL-2-based autoimmune disorders has ended. read more By Nick Paul Taylor Arca Biopharma is down to its last $50 million. With its share price still languishing in the basement, the biotech is pushing ahead with a search for strategic alternatives including the sale of the business. read more By Gabrielle Masson Rigel Pharmaceuticals has handed over $2 million in cash for exclusive licensing rights to Forma Therapeutics’ olutasidenib, an oncology treatment that currently awaits an FDA approval decision. read more By Gabrielle Masson After a meeting with the FDA, Allarity Therapeutics is abandoning hope that its lead clinical asset could be sold as a monotherapy for kidney cancer. read more By Angus Liu After an investigational BridgeBio drug surprisingly failed a clinical trial that would have set up a fight against Pfizer in a rare heart condition, investors have been worrying about Alnylam because of a similar study design. Now, Alnylam has returned partially successful. read more By Andrea Park Armed with a grant from NASA itself, robotic-assisted surgery will soon head for the final frontier. read more By Robert King The Justice Department is suing Idaho to prevent a near-total abortion ban from going into effect later this month, arguing it conflicts with a federal emergency services law. read more By Andrea Park With the pedal firmly to the metal in its U.S. business—thanks in no small part to rival CPAP machine maker Philips’ ongoing recall—ResMed has begun looking beyond its home turf to extend that winning streak. read more By Eric Sagonowsky While lawmakers are busy debating details of the reconciliation bill that may take a serious stab at drug prices, pharmaceutical companies are hustling out a defense. One notable point? The legislation wouldn't bring drug price negotiations in Medicare, a prominent pharma CEO said late last week. Instead, it would introduce price controls, he said. read more Resources Sponsored by: Speid & Associates, Inc. The total immersion, transformative training will take place at the Harvard Club in Boston. VIRTUAL in real time is also available. Contingencies for COVID19 will apply. Register NOW for a large early bird discount www.drugstomarket.com/drugbootcamp. Sponsored by: Thermo Fisher Scientific See how integration of innovative genetic analysis techniques into drug development is driving biopharma & biotech companies ahead. Sponsored by: Triangle Insights Group, LLC Discover how the new partnership between TrialCard and Triangle Insights Group can help you bridge the critical gap between strategy and execution, ensuring commercialization success of your product or therapy. Sponsored by: Nexelis Discover Nexelis’ first-hand perspective on how to develop innovative, agile solutions in vaccine efficacy testing in this exclusive e-book. Sponsored by: Catalent What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent Carla Vozone discusses the significant trends in the OINDP segment including large molecules and novel indications, changes within CDMOs and various challenges facing the industry. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. | 
